352 related articles for article (PubMed ID: 32360993)
1. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
[TBL] [Abstract][Full Text] [Related]
2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
4. Shortening of the electromechanical window in the ketamine/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development.
Morissette P; Regan C; Fitzgerald K; Gerenser P; Travis J; Wang S; Fanelli P; Sannajust F
J Pharmacol Toxicol Methods; 2016; 81():171-82. PubMed ID: 27377419
[TBL] [Abstract][Full Text] [Related]
5. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
Park E; Gintant GA; Bi D; Kozeli D; Pettit SD; Pierson JB; Skinner M; Willard J; Wisialowski T; Koerner J; Valentin JP
Br J Pharmacol; 2018 Feb; 175(4):606-617. PubMed ID: 29181850
[TBL] [Abstract][Full Text] [Related]
6. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Gintant G
Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
[TBL] [Abstract][Full Text] [Related]
8. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
9. Relationship between prolongation of QTc and prolongation of the peak of T (Tp) to the end of T (Te).
Roche BM; Kijtawornrat A; Hamlin RL; Hamlin DM
J Pharmacol Toxicol Methods; 2005; 52(1):178-81. PubMed ID: 15932797
[TBL] [Abstract][Full Text] [Related]
10. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
Vicente J; Stockbridge N; Strauss DG
J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
[TBL] [Abstract][Full Text] [Related]
11. Update on the ECG component of the CiPA initiative.
Vicente J
J Electrocardiol; 2018; 51(6S):S98-S102. PubMed ID: 30121123
[TBL] [Abstract][Full Text] [Related]
12. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the hERG safety margin after 20 years of routine hERG screening.
Leishman DJ; Abernathy MM; Wang EB
J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
[TBL] [Abstract][Full Text] [Related]
15. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
De Clerck F; Van de Water A; D'Aubioul J; Lu HR; van Rossem K; Hermans A; Van Ammel K
Fundam Clin Pharmacol; 2002 Apr; 16(2):125-40. PubMed ID: 12031065
[TBL] [Abstract][Full Text] [Related]
16. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
17. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
[TBL] [Abstract][Full Text] [Related]
18. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
19. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
[TBL] [Abstract][Full Text] [Related]
20. Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole.
Yamamoto K; Tamura T; Imai R; Yamamoto M
Toxicol Sci; 2001 Mar; 60(1):165-76. PubMed ID: 11222883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
